Although SIRT6 has emerging potential as a therapeutic target in cancer, few small molecule inhibitors of SIRT6 have been identified to date, and most of these inhibitors show weak inhibitory activity against SIRT6 and limited antitumor activity [45, 47]. The gene discussed is SIRT6; the disease is cancer.